Inactive Instrument

News Capricor Therapeutics Inc Nasdaq

Equities

US14070B1017

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13	09:01am	AQ
Transcript : Capricor Therapeutics, Inc. - Special Call	Apr. 29
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug	Apr. 24	MT
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	Apr. 24	AQ
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	Apr. 24	CI
Capricor Therapeutics to Present at Upcoming Investor Conferences	Mar. 21	AQ
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference	Mar. 06	AQ
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference	Mar. 06	CI
Capricor: Q4 Earnings Snapshot	Feb. 29	AQ
Transcript : Capricor Therapeutics, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q4 Revenue $12.1M, vs. Street Est of $10.6M	Feb. 29	MT
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Feb. 29	AQ
Capricor Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Capricor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 27	MT
Sector Update: Health Care Stocks Decline Tuesday Afternoon	Feb. 27	MT
Capricor Secures Meeting With FDA on CAP-1002 Manufacturing Plans; Shares Rise	Feb. 27	MT
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy	Feb. 27	AQ
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29	Feb. 22	AQ
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization	Feb. 20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Capricor Therapeutics Inc Nasdaq

Equities

US14070B1017

Summary

Filters